Oric Pharmaceuticals Unveils Rinzimetostat Phase Ib Data, Sets Stage for Phase III Himalayas-1 Trial [Yahoo! Finance]
Oric Pharmaceuticals, Inc. (ORIC)
Company Research
Source: Yahoo! Finance
dose after dose-optimization showed comparable exposure and pharmacodynamic target engagement to 600 mg but a higher incidence of clinically meaningful toxicities at the higher dose. Early activity in post-abiraterone mCRPC included a 47% unconfirmed and 33% confirmed PSA50 (15 evaluable patients) and a 71% =50% ctDNA reduction, with short-term rPFS showing 93% progression-free at 3 months; safety across 33 patients showed only one grade 3 treatment-related event and more GI toxicity at 600 mg versus 400 mg. Oric will launch the registrational Phase III trial Himalayas-1 (rinzimetostat + darolutamide vs physician's choice) after an FDA end-of-phase meeting, targeting a Q2 start and top-line data in late 2027/early 2028. Interested in Oric Pharmaceuticals, Inc.? Here are five stocks we like better. Oric Pharmaceuticals (NASDAQ:ORIC) detailed new dose-optimization results for its PRC2 inhibitor rinzimetostat and outlined plans to begin its first phase III registrational study in
Show less
Read more
Impact Snapshot
Event Time:
ORIC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ORIC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORIC alerts
High impacting Oric Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ORIC
News
- ORIC® Pharmaceuticals Presents Preclinical Data to Support the Potential of Rinzimetostat Across Prostate Cancer and in Emerging Resistance Settings at the 2026 American Association for Cancer Research (AACR) Annual MeetingGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICPR Newswire
- ORIC Investors Have Opportunity to Join ORIC Pharmaceuticals, Inc. Fraud Investigation with the Schall Law FirmBusiness Wire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORICGlobeNewswire
- ORIC Pharmaceuticals, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewswire
ORIC
Earnings
- 2/23/26 - Beat
ORIC
Sec Filings
- 3/31/26 - Form 8-K
- 2/26/26 - Form 4
- 2/24/26 - Form 144
- ORIC's page on the SEC website